Save time and get answers to complex questions with AI chat
Drug patent watch trametinib?Excipients list used in dexamethasone creams?How long have hydroxyzine pamoate been on the market?When is xarelto's patent set to expire roughly?Prolia and osteonecrosis?
See the DrugPatentWatch profile for cosentyx
Cosentyx (secukinumab) for maintenance therapy in approved indications like plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis is given as a 300 mg subcutaneous injection every 4 weeks.[1][2] Patients self-administer after initial training, using pre-filled syringes, auto-injectors, or Sensoready pens.
Treatment begins with loading doses—typically weekly injections at weeks 0, 1, 2, 3—then shifts to every 4 weeks.[1] For some conditions like hidradenitis suppurativa, the loading phase is every 2 weeks before monthly maintenance.[2]
Inject as soon as possible, then resume every 4-week schedule. No double-dosing.[1]
Maintenance continues indefinitely if benefits outweigh risks, with monitoring for infections or side effects like upper respiratory issues.[2] No generic or biosimilar approved yet; Novartis holds patents through 2025 in key markets.[3] [1]: Cosentyx Prescribing Information (Novartis) [2]: FDA Label for Secukinumab [3]: DrugPatentWatch.com - Cosentyx Patents
Other Questions About Cosentyx :